Found Pricing Analysis & Total Cost: Is It Worth What You Pay?

What Does Found Actually Cost Per Month?

Found's pricing has two distinct layers: a platform membership and the cost of any prescribed medication. The membership alone runs approximately $99 per month on a rolling plan, or roughly $79 per month when billed as an annual lump sum of $948. Neither tier includes the medications themselves, which is a point many prospective members miss when reading the advertised price.

The Membership Fee in Detail

The membership covers an initial clinical intake, access to Found's app-based coaching tools, asynchronous messaging with care providers, and follow-up check-ins. The $99 monthly fee is comparable to what Calibrate and Ro Body charge for their base tiers, though the exact services bundled at each price point differ.

Membership fees are not covered by health insurance under standard medical billing codes because they are platform-access fees rather than discrete clinical services. Patients using a Health Savings Account (HSA) or Flexible Spending Account (FSA) may be able to apply those funds, but should verify eligibility with their plan administrator before assuming they can.

Prescription Costs: The Larger Variable

This is where total cost diverges dramatically depending on what Found prescribes. Found's formulary spans several drug classes, and GLP-1 receptor agonists carry the highest price tags.

Compounded semaglutide, sourced through Found's affiliated pharmacy network, typically runs between $200 and $350 per month. Brand-name Wegovy (semaglutide injection 2.4 mg) carries a list price of $1,349.02 per month without insurance, per the FDA-approved prescribing information available on the Novo Nordisk site and cross-referenced with FDA labeling [1]. Brand-name Ozempic (semaglutide 0.5 to 2 mg for type 2 diabetes) lists at roughly $935 per month without coverage.

Non-GLP-1 options Found prescribes, such as bupropion/naltrexone (Contrave) or topiramate, generally cost $30, $80 per month with a GoodRx coupon, which meaningfully changes the value calculation for patients who are not GLP-1 candidates.

What Medications Does Found Prescribe?

Found prescribes across multiple FDA-approved weight-management drug classes, not exclusively GLP-1 agonists. Understanding what you are likely to receive, given your clinical profile, is the most important cost-planning step.

GLP-1 Receptor Agonists

Semaglutide and tirzepatide are the headline medications in Found's formulary. Both carry FDA approval for chronic weight management.

Semaglutide 2.4 mg (Wegovy) received FDA approval in June 2021 for adults with BMI of 30 or above, or BMI of 27 or above with at least one weight-related comorbidity [2]. The STEP-1 trial (N=1,961) showed a mean body weight reduction of 14.9% at 68 weeks with semaglutide 2.4 mg versus 2.4% with placebo (P<0.001) [3].

Tirzepatide 15 mg (Zepbound) received FDA approval for chronic weight management in November 2023. The SURMOUNT-1 trial (N=2,539) found a mean weight reduction of 20.9% at 72 weeks with the 15 mg dose versus 3.1% with placebo [4].

Both drugs are weekly subcutaneous injections. Both require a titration schedule starting at lower doses, which can affect first-month costs if the pharmacy dispenses by individual dose versus a pack.

Non-GLP-1 Options

For patients who do not qualify for or cannot tolerate GLP-1 agonists, Found also prescribes:

• Bupropion/naltrexone extended-release (Contrave): FDA-approved for chronic weight management; generic versions cost $30, $70/month with discount cards.
• Topiramate (off-label for weight management): generic costs under $20/month.
• Metformin (off-label metabolic support): under $10/month generic.
• Phentermine: short-term only per FDA label; generic runs $15, $40/month.

The COR-I trial (N=1,742) showed that bupropion/naltrexone produced 6.1% mean weight loss at 56 weeks versus 1.3% placebo [5], a substantially smaller effect than GLP-1 agonists, which matters when calculating cost-effectiveness.

Compounded vs. Brand-Name Semaglutide

Compounded semaglutide became widely available after the FDA declared Wegovy in shortage. In May 2025, the FDA removed semaglutide from its drug shortage list, triggering a compliance deadline for compounding pharmacies [6]. Found's use of compounded semaglutide may be affected by this regulatory shift. Patients currently on compounded semaglutide through Found should ask their provider what the transition plan is, because the cost gap between compounded ($200, $350/month) and brand-name ($1,349/month) is substantial.

Total Annual Cost Scenarios

Breaking down the full-year cost across realistic scenarios clarifies what "Found pricing" actually means in practice.

Scenario A: Compounded Semaglutide

• Membership: $948/year (annual plan)
• Compounded semaglutide: $300/month x 12 = $3,600/year
• Total: approximately $4,548/year

Scenario B: Non-GLP-1 Medication (e.g., Contrave)

• Membership: $948/year
• Contrave generic: $50/month x 12 = $600/year
• Total: approximately $1,548/year

Scenario C: Brand-Name Wegovy With Insurance

• Membership: $948/year
• Wegovy after insurance copay (assuming $25, $50/month with a manufacturer savings card and commercial insurance): $600/year
• Total: approximately $1,548/year

Note that the Novo Nordisk Wegovy savings card historically covers patients with commercial insurance down to $25 per month for up to 13 pay periods, though terms change and patients should verify current eligibility directly with Novo Nordisk.

Is Found Legit? A Critical Assessment

Found is a registered telehealth company operating in all 50 states and the District of Columbia. Its prescribers are licensed physicians, physician assistants, and nurse practitioners. The platform underwent a significant ownership transition when WW International (Weight Watchers) acquired it in 2023 for approximately $106 million, which affected branding and some operational elements.

Regulatory Standing

Found prescribes FDA-approved medications and, in some cases, compounded preparations from pharmacies that operate under the regulatory oversight of state boards of pharmacy and, for 503A compounders, FDA oversight of ingredient sourcing. The prescribing model is consistent with telehealth standards recognized by the Federation of State Medical Boards' telehealth guidelines [7].

The American Academy of Family Physicians notes that obesity is a chronic disease requiring long-term management, and telehealth platforms can expand access to evidence-based pharmacotherapy for populations who cannot easily access in-person obesity medicine specialists [8].

Quality of Care Concerns

The asynchronous model, where a patient fills out a questionnaire and a provider reviews it without a live visit, is convenient but limits the depth of clinical assessment. Patients with complex metabolic histories, cardiovascular disease, or prior GI conditions may benefit more from an in-person obesity medicine specialist, particularly before starting a GLP-1 agonist.

The HealthRX clinical team uses the following decision framework when evaluating whether a direct-to-consumer telehealth obesity platform is appropriate for a given patient. Patients who answer "yes" to two or more of the following questions should consider an in-person obesity medicine consultation before enrolling in any telehealth-only program:

1. Do you have a personal history of medullary thyroid carcinoma or MEN2 syndrome?
2. Do you have active pancreatitis or a history of severe pancreatitis?
3. Are you currently managing heart failure (NYHA Class III or IV)?
4. Have you had a prior serious adverse event on a GLP-1 or GIP/GLP-1 agonist?
5. Are you on three or more medications with known interactions with GLP-1 agonists (e.g., oral contraceptives, cyclosporine, warfarin)?

Found vs. Alternatives: Cost and Value Comparison

Direct comparison requires looking at membership cost, drug access, and the clinical model side by side.

Found vs. Calibrate

Calibrate charges approximately $199/month, which includes a one-year metabolic reset program. Drug costs are separate, similar to Found. Calibrate's model emphasizes four pillars (food, sleep, exercise, emotional health) and requires a live video visit with a physician before prescribing. That live visit requirement may improve clinical screening but adds friction.

For patients who qualify for GLP-1 medications, the drug cost is the same at both platforms because it is determined by pharmacy pricing, not the platform. The platform fee at Calibrate is roughly double Found's base rate.

Found vs. Ro Body

Ro Body charges $145/month for its metabolic program plus separate drug costs. Ro dispenses through its own pharmacy, which allows tighter integration and sometimes faster titration support. Ro has historically offered compounded semaglutide at a similar price point to Found.

Found vs. Sesame or GoodRx Care

Neither Sesame nor GoodRx Care operates a structured obesity program, but both allow patients to book telehealth visits with physicians who can prescribe weight-loss medications. A Sesame obesity visit runs $30, $75. A patient who knows what they want and can manage their own titration may pay significantly less through this model, though they lose the app-based coaching layer.

Found vs. In-Person Obesity Medicine Specialist

A board-certified obesity medicine specialist visit costs $150, $400 per visit without insurance, but many carry insurance coverage, particularly for patients with obesity-related comorbidities. The Obesity Medicine Association's treatment guidelines recommend intensive behavioral intervention combined with pharmacotherapy for best outcomes [9]. In-person specialists can bill insurance for the office visit, which online platform membership fees cannot.

Does Insurance Cover Found?

Found's membership fee is not typically covered by insurance. Prescription medications, however, may be covered depending on your plan.

Commercial Insurance

As of 2024, approximately 27% of large employer-sponsored health plans in the United States cover GLP-1 medications specifically for obesity (as distinct from diabetes), according to a KFF survey of employer health benefits [10]. Coverage for obesity pharmacotherapy has expanded but remains inconsistent. Patients should call the member services number on their insurance card and specifically ask whether Wegovy or Zepbound is on formulary for obesity.

Blue Cross Blue Shield (BCBS) plans are Found's primary insurance partner. Specific BCBS plans have negotiated rates with Found, potentially reducing drug costs. The terms vary by state and BCBS affiliate, so patients should confirm directly with their local plan whether the Found partnership applies to their specific policy.

Medicare and Medicaid

Medicare Part D did not cover anti-obesity medications historically, but the Treat and Reduce Obesity Act, if passed into law, would change that. As of July 2025, Medicare coverage for GLP-1 medications for obesity alone (not diabetes) remains limited, though some Medicare Advantage plans have begun adding coverage. Medicaid coverage varies by state.

Found GLP-1 Weight Loss: What the Evidence Says About Outcomes

Found does not publish independent outcome data from its own patient cohort, which makes it impossible to verify platform-specific efficacy claims. The relevant efficacy data comes from the clinical trials of the drugs Found prescribes.

Semaglutide Outcomes

The STEP program across four trials consistently showed clinically meaningful weight loss. STEP-1 (N=1,961): 14.9% mean weight loss at 68 weeks [3]. STEP-3 (N=611), which combined semaglutide 2.4 mg with intensive behavioral therapy, showed 16.0% mean weight loss at 68 weeks [11]. STEP-4 (N=803) demonstrated that patients who discontinued semaglutide after 20 weeks regained two-thirds of their lost weight by week 68 [12], a finding directly relevant to the cost question because it suggests the drug is a long-term commitment, not a short-term fix.

Tirzepatide Outcomes

SURMOUNT-1 (N=2,539): tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks versus 3.1% with placebo (P<0.001) [4]. The SURMOUNT-4 trial (N=670) showed that patients who continued tirzepatide after a 36-week lead-in maintained 5.5% additional weight loss versus a 14.8% regain in the placebo switch group at 88 weeks [13], again underscoring the long-term cost implication.

What This Means for Cost Planning

Given that STEP-4 and SURMOUNT-4 both demonstrate significant weight regain after discontinuation, patients considering Found should budget for long-term, potentially indefinite medication use. At $300/month for compounded semaglutide plus $99 membership, the two-year cost approaches $9,576 before any insurance offset. At brand-name pricing without insurance, two-year costs can exceed $35,000.

The Endocrine Society's clinical practice guideline on obesity pharmacotherapy states: "Anti-obesity medications are indicated as long-term therapy because obesity is a chronic disease. We suggest continuation beyond 3 months only if the person has lost at least 5% of baseline body weight" [14].

Red Flags and Limitations to Know Before You Sign Up

No telehealth platform is without limitations, and Found has several worth naming directly.

No Live Video Required for Initial Prescription

Found's standard intake is asynchronous. A licensed provider reviews your health history form and can issue a prescription without speaking with you. This is legal and common in telehealth, but it means the prescriber has less information than a clinician who examined you. Patients with borderline contraindications may be approved when they might benefit from a more careful evaluation.

Compounded Semaglutide Regulatory Risk

As noted, the FDA removed semaglutide from the drug shortage list in May 2025 [6]. Compounding pharmacies dispensing copies of Wegovy are operating under increasing legal pressure. Found has not publicly disclosed its contingency plan for patients currently on compounded semaglutide if compounding is restricted. Patients should ask this question before enrolling.

Cancellation and Refund Terms

Found's annual plan is paid upfront and refund terms are limited. Patients who enroll on an annual plan and then find the platform unsuitable, or who are not prescribed the medication they expected, may find it difficult to recover the membership fee. Monthly billing at $99 offers more flexibility.

App Dependency

Found's coaching and follow-up system is app-based. Patients who prefer or require telephone-based care, or who have limited smartphone access, may find the platform less usable.

Found Reviews: What Actual Patients Report

Found holds a 3.7-out-of-5 rating on Trustpilot as of mid-2025, with 2,100+ reviews. Common positive themes include quick prescription turnaround, responsive app messaging, and convenience. Common negative themes include billing confusion around medication costs not being included in the membership fee, difficulty reaching providers when side effects arise, and frustration around compounded semaglutide supply disruptions.

The billing confusion point is clinically significant. Patients who enrolled expecting a single all-in monthly fee and then received a separate pharmacy bill were caught off guard. Transparent pre-enrollment cost counseling is an area where Found can improve relative to platforms that quote total cost estimates upfront.